Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
BioSpace
HIV remained Gilead's strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
pharminent
August 5, 2026 (Last updated: August 5, 2026)
BioSpace
HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
